Magnetic Resonance Imaging in Comparison to Clinical Palpation in Assessing the Response of Breast Cancer to Epirubicin Primary Chemotherapy

[1] Bonadonna G(1990)Primary chemotherapy to avoid mastectomy in tumors with diameter of three centimetres and more J Natl Cancer Inst 82 1539-1545

[2] Veronesi U(1998)Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672-2685

[3] Brambilla C(2001)Preoperative (neoadjuvant) chemotherapy in patients with breast cancer Semin Oncol 28 389-399

[4] Ferrari L(1998)Primary chemotherapy in operable breast cancer: eight years experience at the Milan Cancer Institute J Clin Oncol 16 93-100

[5] Luini A(1995)Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer J Clin Oncol 13 537-540

[6] Greco M(2001)Neoadjuvant therapy in breast cancer: can we define its role? Oncologist 6 36-39

[7] Bartoli C(2000)p53 but not bcl2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients Clin Cancer Res 6 2751-2758

[8] Coopmans de Y(2001)Relationship between tumor shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer Br J Cancer 85 1106-1112

[9] Zucali R(1984)Problems in evaluating response of primary breast cancer to systemic therapy Breast Cancer Res Treat 4 309-313

[10] Rilke F(2001)Breast cancer imaging: the future Semin Oncol 28 221-228

[1] Bonadonna G(1990)Primary chemotherapy to avoid mastectomy in tumors with diameter of three centimetres and more J Natl Cancer Inst 82 1539-1545

[2] Veronesi U(1998)Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672-2685

[3] Brambilla C(2001)Preoperative (neoadjuvant) chemotherapy in patients with breast cancer Semin Oncol 28 389-399

[4] Ferrari L(1998)Primary chemotherapy in operable breast cancer: eight years experience at the Milan Cancer Institute J Clin Oncol 16 93-100

[5] Luini A(1995)Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer J Clin Oncol 13 537-540

[6] Greco M(2001)Neoadjuvant therapy in breast cancer: can we define its role? Oncologist 6 36-39

[7] Bartoli C(2000)p53 but not bcl2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients Clin Cancer Res 6 2751-2758

[8] Coopmans de Y(2001)Relationship between tumor shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer Br J Cancer 85 1106-1112

[9] Zucali R(1984)Problems in evaluating response of primary breast cancer to systemic therapy Breast Cancer Res Treat 4 309-313

[10] Rilke F(2001)Breast cancer imaging: the future Semin Oncol 28 221-228